BD (Becton, Dickinson and Company) announced on October 14, 2024, the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits. This solution aims to automate and standardize large-scale, single-cell discovery studies.
The automated solution, developed in collaboration with Hamilton, includes the newly released BD® OMICS-One XT WTA Assay and the Hamilton® Microlab™ NGS STAR automated liquid handling platform. This integration standardizes traditionally manual processes, speeding up the generation of material for genetic sequencing.
By automating complex DNA library preparation, researchers can scale sample throughput and achieve more consistent results, minimizing variability. This advancement is crucial for accelerating discovery in critical areas such as oncology and immunology, leveraging the widespread installation of the NGS STAR platform in laboratories globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.